Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosis
Multiple Sclerosis Journal – Experimental, Translational and Clinical · 2026-07 · 12 (3)
DOI: 10.1177/20552173261464369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal – Experimental, Translational and Clinical, online erschienen am 08.08.2026. Verfasst von Ming-Hui Tai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Background
Treatment schedule complexity and route of administration may influence patient adherence and persistence. Limited real-world evidence exists comparing these outcomes across treatments for multiple sclerosis (MS).
Objective
To examine 18- and 24-month adherence/persistence of ofatumumab (OMB) and other approved disease-modifying therapies (DMTs).
Methods
Optum Clinformatics® Data Mart data were used to identify adult patients with MS who initiated treatment with an approved DMT from August 20, 2019, to December 31, 2023. Patients were stratified into four treatment groups: OMB, infusion DMTs, oral DMTs, and other injectable DMTs.
Results
After propensity score matching, adherence to OMB was significantly higher than to oral DMTs (18 months: 73% vs. 51% [ p < .001]; 24 months: 69% vs. 47% [ p < .001]) and was also higher with OMB than with other injectable agents (18 months: 74% vs. 40% [ p < .001]; 24 months: 70% vs. 35% [ p < .001]). Adherence to OMB and infusion DMTs was comparable (18 months: 74% vs. 70% [ p = . 31]; 24 months: 70% vs. 65% [ p = . 24]). Similar patterns were observed for persistence between the groups.
Conclusion
These findings suggest OMB is a convenient, effective, self-administered alternative to infusion therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- STATLOG Inc, Montreal, QC, Canada.
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Tai, M. H., Brown, B., Taiji, R., Faucher, A., Vekeman, F., Ionescu-Ittu, R., & Gadkari, A. (2026). Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(3). https://doi.org/10.1177/20552173261464369
Vancouver
Tai MH, Brown B, Taiji R, Faucher A, Vekeman F, Ionescu-Ittu R, et al. Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2026;12(3). doi:10.1177/20552173261464369
BibTeX
@article{Tai2026,
author = {Tai, Ming-Hui and Brown, Brandon and Taiji, Riley and Faucher, Ariane and Vekeman, Francis and Ionescu-Ittu, Raluca and Gadkari, Abhijit},
title = {Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosis},
journal = {Multiple Sclerosis Journal – Experimental, Translational and Clinical},
year = {2026},
volume = {12},
number = {3},
doi = {10.1177/20552173261464369}
}
EUVIMED